Feb 13, 2023 / 04:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q3 FY '23 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi -
Thank you, moderator. Good morning, everyone, and a very warm welcome to the Q3 FY '23 results conference call of Glenmark Pharmaceuticals Limited. Before we start the call, a review of the operations for the company for quarter ended December 31, 2022. For the third quarter of FY '23, Glenmark's consolidated revenue from operations was at INR 34,639 million as against INR 31,734 million in the corresponding quarter last year, recording a growth of 9.2%. For 9 months of FY '23, Glenmark's consolidated revenue was at INR 96,164 million as against INR 92,858 million, recording a growth of 3.6% year-on-year.
We start with the formulation business and we'll start off with India. Sales from the
Q3 2023 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Feb 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers